# EDGAR Filing Document

**Accession Number:** 0001326732
**File Stem:** 0001326732-25-000057
**Filing Date:** 2025-6
**Character Count:** 7290
**Document Hash:** 88723d719662b2fa51abacb745e29c22
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001326732-25-000057.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001326732-25-000057

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250612

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Xencor Inc
- **CENTRAL INDEX KEY:** 0001326732
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 201622502
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36182
- **FILM NUMBER:** 251046311

**BUSINESS ADDRESS:**
- **STREET 1:** 465 N. HALSTEAD ST.
- **STREET 2:** SUITE 200
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91107
- **BUSINESS PHONE:** 626-305-5900

**MAIL ADDRESS:**
- **STREET 1:** 465 N. HALSTEAD ST.
- **STREET 2:** SUITE 200
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91107

?xml version='1.0' encoding='ASCII'? xncr-20250612

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

___________________________________________________

**FORM 8-K**

___________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 12, 2025**

___________________________________________________

**XENCOR, INC.**

(Exact name of registrant as specified in its charter)

___________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36182** | **20-1622502** |
| (State or Other Jurisdiction of <br>Incorporation) | (Commission <br>File Number) | (IRS Employer <br>Identification Number) |

---

---

| | |
|:---|:---|
| **465 North Halstead Street, Suite 200** <br>**Pasadena, California** | **91107** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**(626) 305-5900**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

___________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock, par value $0.01 per share | XNCR | Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 12, 2025, Xencor, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders. A total of 67,366,750 shares of the Company's common stock were present or represented by proxy at the meeting, which represents approximately 94.68% of the 71,151,714 shares of the Company's common stock that were outstanding and entitled to vote at the meeting as of the record date of April 15, 2025. Stockholders considered the three proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2025 (the "Proxy Statement").

**Proposal 1. Election of Directors**

The Company's stockholders elected the eight persons listed below as directors, each to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | | **Votes** | **Broker** |
| | **Votes for** | **Withheld** | **Non-Votes** |
| Dr. Bassil I. Dahiyat | 63855868 | 328348 | 3182534 |
| Dr. Ellen G. Feigal | 63164762 | 1019454 | 3182534 |
| Dr. Kevin C. Gorman | 63783279 | 400937 | 3182534 |
| Mr. Kurt A. Gustafson | 61133003 | 3051213 | 3182534 |
| Dr. Barbara Klencke | 62638045 | 1546171 | 3182534 |
| Dr. A. Bruce Montgomery | 61202390 | 2981826 | 3182534 |
| Mr. Richard J. Ranieri | 63039104 | 1145112 | 3182534 |
| Mr. Todd E. Simpson | 64122708 | 61508 | 3182534 |

---

**Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm**

The Company's stockholders ratified the selection by the Audit Committee of the Board of Directors of KPMG LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | | | **Broker** |
| **Votes for** | **Votes Against** | **Abstentions** | **Non-Votes** |
| 66,996,453 | 285,976 | 84,321 | 0 |

---

**Proposal 3. Approval of the Amendment and Restatement of the Xencor, Inc. 2023 Equity Incentive Plan to Increase the Number of Authorized Shares Available for Issuance thereunder by 3,000,000 Shares**

The Company's stockholders approved the amendment and restatement of the Xencor, Inc. 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 3,000,000 shares. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | | | **Broker** |
| **Votes for** | **Votes Against** | **Abstentions** | **Non-Votes** |
| 49,263,095 | 14,898,697 | 22,424 | 3,182,534 |

---

**Proposal 4. Advisory Vote on the Compensation of the Company's Named Executive Officers**

The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of its named executive officers as disclosed in the Proxy Statement. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | | | **Broker** |
| **Votes for** | **Votes Against** | **Abstentions** | **Non-Votes** |
| 62,837,866 | 1,313,362 | 32,988 | 3,182,534 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 13, 2025 | **XENCOR, INC.** | **XENCOR, INC.** |
|  | By: | /s/ Celia Eckert |
|  |  | Celia Eckert |
|  |  | General Counsel & Corporate Secretary |

---